Literature DB >> 20878367

Familial follicular cell tumors: classification and morphological characteristics.

Vânia Nosé1.   

Abstract

Familial follicular cell-derived well-differentiated thyroid cancer, papillary (PTC), and follicular thyroid carcinomas (FTC), accounts for 95% of thyroid malignancies. The majority of are sporadic, and at least 5% of these patients will have familial disease. Familial thyroid syndromes are classified into familial medullary thyroid carcinoma (FMTC), derived from calcitonin-producing C cells, and familial follicular cell tumors or non-medullary thyroid carcinoma (FNMTC), derived from follicular cells. Twenty-five percent of patients with medullary thyroid cancer (MTC) have a familial form; however, this accounts for only 1% of all patients with thyroid cancer. The familial follicular cell-derived lesions or familial non-medullary thyroid cancer can be divided into two clinical-pathological groups. The first group includes familial syndromes characterized by a predominance of non-thyroidal tumors, such as familial adenomatous polyposis (FAP), PTEN-hamartoma tumor syndrome (Cowden disease; PHTS), Carney complex, Werner syndrome, and Pendred syndrome. The second group includes familial syndromes characterized by predominance of papillary thyroid carcinoma (PTC), such as pure fPTC, fPTC associated with papillary renal cell carcinoma, and fPTC with multinodular goiter. Most of the progress in the genetics of familial thyroid cancer has been in patients with MTC. This is usually a component of multiple endocrine neoplasias IIA or IIB, or as pure familial medullary thyroid carcinoma syndrome. The genetic events in the familial C-cell-derived tumors are known and genotype-phenotype correlations are well established. The mutations in patients with isolated NMFTC have not been as well defined as in MTC. In many cases, patients have a known familial syndrome that has defined risk for thyroid cancer. The clinician must be knowledgeable in recognizing the possibility of an underlying familial syndrome when a patient presents with thyroid cancer. Some characteristic thyroid morphologic findings should alert the pathologist of a possible familial cancer syndrome, which may lead to further molecular genetics evaluation.

Entities:  

Mesh:

Year:  2010        PMID: 20878367     DOI: 10.1007/s12022-010-9135-6

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  28 in total

1.  Thyroid pathologic findings in patients with Cowden disease.

Authors:  H R Harach; I Soubeyran; A Brown; D Bonneau; M Longy
Journal:  Ann Diagn Pathol       Date:  1999-12       Impact factor: 2.090

2.  Does familial non-medullary thyroid cancer adversely affect survival?

Authors:  Frederic Triponez; Mariwil Wong; Cord Sturgeon; Nadine Caron; David G Ginzinger; Mark R Segal; Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

3.  Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome.

Authors:  C D Malchoff; M Sarfarazi; B Tendler; F Forouhar; G Whalen; V Joshi; A Arnold; D M Malchoff
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

Review 4.  The Werner syndrome. A model for the study of human aging.

Authors:  J O Nehlin; G L Skovgaard; V A Bohr
Journal:  Ann N Y Acad Sci       Date:  2000-06       Impact factor: 5.691

5.  Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid.

Authors:  J R Burgess; A Duffield; S J Wilkinson; R Ware; T M Greenaway; J Percival; L Hoffman
Journal:  J Clin Endocrinol Metab       Date:  1997-02       Impact factor: 5.958

6.  Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population.

Authors:  Shinya Uchino; Shiro Noguchi; Hitoshi Kawamoto; Hiroyuki Yamashita; Shin Watanabe; Hiroto Yamashita; Shigeru Shuto
Journal:  World J Surg       Date:  2002-04-30       Impact factor: 3.352

Review 7.  Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm.

Authors:  H R Harach; G T Williams; E D Williams
Journal:  Histopathology       Date:  1994-12       Impact factor: 5.087

Review 8.  Familial thyroid carcinoma: a diagnostic algorithm.

Authors:  Jorge Dotto; Vânia Nosé
Journal:  Adv Anat Pathol       Date:  2008-11       Impact factor: 3.875

9.  Familial adenomatous polyposis-associated thyroid cancer: a clinical, pathological, and molecular genetics study.

Authors:  C Soravia; S L Sugg; T Berk; A Mitri; H Cheng; S Gallinger; Z Cohen; S L Asa; B V Bapat
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

10.  Two common and three novel PDS mutations in Thai patients with Pendred syndrome.

Authors:  T Snabboon; W Plengpanich; S Saengpanich; S Sirisalipoch; S Keelawat; S Sunthornyothin; W Khovidhunkit; S Suwanwalaikorn; V Sridama; V Shotelersuk
Journal:  J Endocrinol Invest       Date:  2007-12       Impact factor: 4.256

View more
  5 in total

Review 1.  Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.

Authors:  Vania Nosé; Anthony Gill; José Manuel Cameselle Teijeiro; Aurel Perren; Lori Erickson
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

2.  Association between benign thyroid and endocrine disorders and subsequent risk of thyroid cancer among 4.5 million U.S. male veterans.

Authors:  Sanjeeve Balasubramaniam; Elaine Ron; Gloria Gridley; Arthur B Schneider; Alina V Brenner
Journal:  J Clin Endocrinol Metab       Date:  2012-05-08       Impact factor: 5.958

3.  Familial follicular cell-derived thyroid carcinoma.

Authors:  Eun Ju Son; Vânia Nosé
Journal:  Front Endocrinol (Lausanne)       Date:  2012-05-03       Impact factor: 5.555

Review 4.  Emerging Biomarkers in Thyroid Practice and Research.

Authors:  Shipra Agarwal; Andrey Bychkov; Chan-Kwon Jung
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

5.  Thyroid Nodule Management: Thyroid-Stimulating Hormone, Ultrasound, and Cytological Classification System for Predicting Malignancy.

Authors:  Mohamed Abdulaziz Al Dawish; Asirvatham Alwin Robert; Mohammed A Thabet; Rim Braham
Journal:  Cancer Inform       Date:  2018-03-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.